Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Biotech

Biotech

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Top Stories

What’s Going On With Dermatitis-Focused RAPT Therapeutics Stock On Thursday?

By Vandana Singh
May 9, 2:12 PM
RAPT Therapeutics closes Phase 2 trials for zelnecirnon in atopic dermatitis & asthma following FDA clinical hold due to liver failure.

RAPT

Read More
2 minute read
  • Biotech
  • Earnings
  • General
  • Guidance
  • Health Care
  • Movers
  • News
  • Top Stories

Japan’s Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%

By Vandana Singh
May 9, 1:46 PM
Takeda Pharmaceutical (NYSE: TAK) reveals fiscal year 2023 results & restructuring plan. Revenue up 5.9%, net profit down 54.6%. Expecting operating profit of 225 billion yen in 2024.

TAK

Read More
1 minute read
  • Biotech
  • General
  • Global
  • News

Jaguar Health Announces Submission Of Clinical Trial Applications For Crofelemer To Treat Rare Disease Indications Microvillus Inclusion Disease And Short Bowel Syndrome In Europe

By Benzinga Newsdesk
May 9, 10:40 AM
Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and SBSSAN FRANCISCO, CA / ACCESSWIRE / May 9, 2024 / Jaguar

JAGX

Read More
1 minute read
  • Biotech
  • General
  • News

Capricor Therapeutics To Present Exosome Platform Updates At ASGCT 27th Annual Meeting; Preclinical Findings Show Exosome-Based Therapeutic Approach For The Treatment Of Arginase-1 Deficiency

By Benzinga Newsdesk
May 9, 9:39 AM
-Preclinical findings show exosome-based therapeutic approach for the treatment of arginase-1 deficiency (ARG1-D)- -Presentation to be featured in an oral session being held on May 9, 2024-SAN DIEGO, May 09, 2024

CAPR

Read More
1 minute read
  • Biotech
  • General
  • News

Poseida Highlights Progress On Its Genetic Medicine Programs At The American Society For Gene And Cell Therapy 27th Annual Meeting

By Benzinga Newsdesk
May 9, 9:35 AM
Early non-human primate (NHP) data for P-KLKB1-101 demonstrate successful liver gene editing approaching human therapeutic range with a favorable safety and tolerability profilePreclinical P-FVIII-101 data highlight

PSTX

Read More
2 minute read
  • Biotech
  • General
  • News

Surrozen Presents Data Demonstrating The Promise Of Antibody-Based Wnt Mimetics In Treating Cornea Endothelial Dystrophies And Dry Eye Disease At The ARVO Annual Meeting

By Benzinga Newsdesk
May 9, 9:21 AM
In preclinical models of cornea endothelial dystrophies, a Surrozen antibody-based Wnt mimetic reduced corneal edema and stimulated endothelial cell proliferation in the cornea Surrozen's antibody based Wnt mimetic

SRZN

Read More
1 minute read
  • Biotech
  • General
  • News

Ascendis Pharma A/S Clinical And Quality-Of-Life Data For TransCon PTH-Treated Adults With Chronic Hypoparathyroidism To Be Presented At ECE 2024

By Benzinga Newsdesk
May 9, 9:17 AM
Ascendis Pharma A/S (NASDAQ:ASND) today announced that new TransCon PTH (palopegteriparatide) data supporting clinical and quality-of-life benefits in adult patients with chronic hypoparathyroidism will be presented at

ASND

Read More
1 minute read
  • Biotech
  • General
  • News

Akoya Biosciences And NeraCare Enter Exclusive Agreement To Enable Personalized Therapy Selection For Early-Stage Melanoma Patients

By Benzinga Newsdesk
May 9, 9:02 AM
Akoya Biosciences, Inc. (NASDAQ:AKYA), The Spatial Biology Company®, and NeraCare, a leading developer of laboratory tests for the prognosis of melanoma patients, announced an exclusive agreement today under which

AKYA

Read More
1 minute read
  • Biotech
  • General
  • News

Rani Therapeutics To Present Data On Oral Delivery Of An Ustekinumab Biosimilar Via The RaniPill Capsule At Digestive Disease Week 2024

By Benzinga Newsdesk
May 9, 9:00 AM
Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present clinical

RANI

Read More
2 minute read
  • Biotech
  • General
  • News

Mind Medicine Presents New Studies At ISPOR 2024 Showing Growing Burden And Impact Of Generalized Anxiety Disorder In The U.S.

By Benzinga Newsdesk
May 9, 8:56 AM
-GAD Diagnosis Increases Healthcare Costs and Decreases Work Productivity and Health-Related Quality of Life--People with Undiagnosed GAD Incur Even Higher Total Healthcare Costs than those Diagnosed with

MNMD

Posts pagination

Previous 1 … 35 36 37 … 733 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service